Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.60 |
| ▸ | SCD | O00767 | 11/20 | 0.57 |
| ▸ | CBFB | Q13951 | 1/20 | 0.55 |
| ▸ | FADS1 | O60427 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817421 | 0.83 | NPBWR1 (0.42) | NPBWR1SCDCBFB | |
| SCHEMBL4681427 | 0.83 | HDAC6 (0.60) | NPBWR1SCDCBFB | |
| SCHEMBL1160169 | 0.83 | HDAC6 (0.60) | NPBWR1SCDCBFB | |
| SCHEMBL3391201 | 0.83 | CA12 (0.53) | NPBWR1SCD | |
| SCHEMBL16134729 | 0.83 | KDM4E (0.48) | NPBWR1SCDCBFB | |
| Water SCHEMBL28362651 | 0.82 | HDAC6 (0.58) | NPBWR1SCDCBFB | |
| SCHEMBL8021452 | 0.82 | HDAC6 (0.58) | NPBWR1SCDCBFB | |
| Water SCHEMBL18890706 | 0.82 | NPBWR1 (0.41) | NPBWR1SCDCBFB | |
| SCHEMBL17702662 | 0.81 | NPBWR1 (0.61) | NPBWR1SCDCBFBFADS1 | |
| SCHEMBL8498393 | 0.80 | NPBWR1 (0.60) | NPBWR1SCDCBFBFADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115136-A1 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2016-04-28 | — | — | US | disclosed |
| US-6043242-A | TREATING A MAMMAL AFFLICTED WITH A DISEASE BASED ON HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-28 | — | — | US | disclosed |
| EP-0946559-A2 | IMIDAZOPYRIDAZINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028299-A2 | IMIDAZOPYRIDAZINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115136-A1 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO | LPO, NOTUM, FARS2 | NPBWR1 4869/4885SCD 556/4885CBFB 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.